Welcome to LookChem.com Sign In|Join Free
  • or
CP 481715, also known as 3-Cyano-4-(pyridin-4-yl)-6-(trifluoromethyl)pyridin-2-amine, is a synthetic chemical compound belonging to the group of pyridine derivatives. It is a potent and selective inhibitor of the enzyme JAK2 (Janus kinase 2), which plays a critical role in the development and progression of myeloproliferative neoplasms and other inflammatory diseases. CP 481715 has shown promising results in preclinical studies for the treatment of myelofibrosis, a chronic and progressive bone marrow disorder. Its mechanism of action involves the inhibition of JAK2-mediated signaling pathways, which are essential for the proliferation and survival of abnormal hematopoietic cells. CP 481715 has the potential to be developed as a targeted therapy for myelofibrosis and other JAK2-driven diseases, and further research is ongoing to evaluate its safety and efficacy in clinical trials.

212790-31-3

Post Buying Request

212790-31-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

212790-31-3 Usage

Uses

Used in Pharmaceutical Industry:
CP 481715 is used as a targeted therapy for the treatment of myelofibrosis, a chronic and progressive bone marrow disorder. It works by inhibiting the JAK2 enzyme, which is involved in the development and progression of myeloproliferative neoplasms and other inflammatory diseases.
Used in Research Applications:
CP 481715 is used as a research tool to study the role of JAK2 in various diseases and to evaluate its potential as a therapeutic agent for the treatment of JAK2-driven conditions. It is also used to investigate the underlying mechanisms of JAK2-mediated signaling pathways and their contribution to the proliferation and survival of abnormal hematopoietic cells.

Check Digit Verification of cas no

The CAS Registry Mumber 212790-31-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,2,7,9 and 0 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 212790-31:
(8*2)+(7*1)+(6*2)+(5*7)+(4*9)+(3*0)+(2*3)+(1*1)=113
113 % 10 = 3
So 212790-31-3 is a valid CAS Registry Number.

212790-31-3Downstream Products

212790-31-3Relevant academic research and scientific papers

Process development of CP-481715, a novel CCR1 antagonist

Li, Bryan,Andresen, Brian,Brown, Matthew F.,Buzon, Richard A.,Chiu, Charles K.-F.,Couturier, Michel,Dias, Eric,Urban, Frank J.,Jasys, V. John,Kath, John C.,Kissel, William,Le, Tung,Li, Z. Jane,Negri, Joanna,Poss, Christopher S.,Tucker, John,Whritenour, David,Zandi, Kathleen

, p. 466 - 471 (2012/12/25)

Process development for the synthesis of 2-quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)-methyl]-2, 7-dihydroxy-7-methyloctyl] is described. An optimized and streamlined process starting from lactone 2 was developed: Lactone

Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making

-

Page 16, (2010/02/05)

This invention relates to dihydroxyhexanoic acid derivatives and their intermediates, as well as to methods of preparing such compounds. Additionally, present invention relates to removing a protecting group from a protected amine wherein the method comprises reacting the protected amine with phosphoric acid.

Novel CCR1 antagonists with improved metabolic stability

Brown, Matthew F.,Avery, Mike,Brissette, William H.,Chang,Colizza, Kevin,Conklyn, Maryrose,DiRico, Amy P.,Gladue, Ronald P.,Kath, John C.,Krueger, Suzanne S.,Lira, Paul D.,Lillie, Brett M.,Lundquist, Greg D.,Mairs, Erin N.,McElroy, Eric B.,McGlynn, Molly A.,Paradis, Timothy J.,Poss, Christopher S.,Rossulek, Michelle I.,Shepard, Richard M.,Sims, Jeff,Strelevitz, Timothy J.,Truesdell, Susan,Tylaska, Laurie A.,Yoon, Kwansik,Zheng, Deye

, p. 2175 - 2179 (2007/10/03)

The synthesis, biological activity, and pharmacokinetic profile of novel CCR1 antagonists are described.

CRYSTAL FORMS OF QUINOXALINE-2-CARBOXYLIC ACID [4-CARBAMOYL-1-(3-FLUOROBENZYL)-2,7-DIHYDROXY-7-METHYL-OCTYL]-AMIDE

-

Page 22-23, (2010/02/06)

The invention relates to crystal forms of quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluorobenzyl)-2,7-dihydroxy-7-methyl-octyl]-amide, useful in treating or preventing a disorder or condition by antogonizing the CCR1 receptor, and to their methods o

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 212790-31-3